Mankind Pharma has reported results for fourth quarter (Q4) and year ended March 31, 2025.
The company has reported 18.28% decline in its net profit at Rs 382.46 crore for the quarter under review as compared to Rs 468.02 crore for the same quarter in the previous year. However, total income of the company increased by 12.11% at Rs 2,345.91 crore for Q4FY25 as compared to Rs 2,092.43 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 10.90% decline in its net profit at Rs 424.65 crore for fourth quarter ended March 31, 2025 as compared to Rs 476.59 crore for the same quarter in the previous year. However, total income of the company increased by 32.47% at Rs 3,330.70 crore for Q4FY25 as compared to Rs 2,514.39 crore for the corresponding quarter previous year.
For the year ended March 31, 2025, the company has reported 3.69% rise in its net profit at Rs 1,945.48 crore as compared to Rs 1,876.16 crore for the previous year. The total income of the company increased by 12.26% at Rs 9,991.01 crore for year under review as compared to Rs 8,899.75 crore for year ended March 31, 2024.
For the year ended March 31, 2025, on the consolidated basis, the company has reported 3.57% rise in its net profit at Rs 2,011.12 crore as compared to Rs 1,941.77 crore for the previous year. The total income of the company increased by 20.91% at Rs 12,744.23 crore for year under review as compared to Rs 10,540.66 crore for year ended March 31, 2024.
